P-892. Reality of Resistance Data: Practical Applications of Risk Adjusted Antimicrobial Resistance Data Using The National Healthcare Safety Network Antimicrobial Use and Resistance Module

Abstract Background Beginning in 2024, US hospitals were required to participate in the CDC National Healthcare Safety Network (NHSN) antimicrobial use and resistance (AUR) module, which captures data on antimicrobial use (AU) and targeted antimicrobial resistance (AR) results. The AUR module outputs provide facility-level risk adjustment that enables inter-hospital benchmarking. While many stewards have experience using AU, end users are less familiar with AR module outputs. Also, national aggregate data reports of AR are not yet available. We describe an initial year of risk-adjusted output from the NHSN AR option for our network of 46 hospitals included in the Duke Antimicrobial Stewardship Outreach Network (DASON) NHSN Group. Methods AR data for each facility were reported in monthly increments following NHSN protocol specifications. A dataset was generated and reports for two risk-adjusted AR metrics were extracted: standardized resistant infection ratio (SRIR) and pathogen-specific standardized infection ratio (pSIR) for 2024. These observed to expected (O:E) ratios are calculated for hospital onset (collected after day 3 of admission) isolates. Data were summarized using descriptive measures. Results SRIRs were available for seven drug-resistant pathogen groups and three of the four anatomic sites captured in NHSN (blood, urine and lower respiratory tract). pSIRs were calculated for the same three sites for four pathogen groups. No risk adjusted metrics were available for cerebrospinal fluid specimens. Distributions for each of the 21 SRIR and 12 pSIR categories across 46 DASON hospitals (Tables 1 & 2) demonstrate great variability among hospitals. Specifically, effects of small populations on predicted isolate numbers were common in our community hospital network. Of 966 predicted isolate calculations (SRIR denominators) for 2024, (531) 55% were predicted to be less than one. Similarly, for the 552 predicted hospital onset pathogens, 132 (24%) were predicted to be less than one. Conclusion Early experience with AR data suggests that low predicted numbers of isolates may result in initially high observed to expected ratios. More experience on how to use and interpret hospitals’ AR risk-adjusted metrics in routine stewardship and prevention work is needed. Disclosures Elizabeth Dodds Ashley, PharmD, MHS, HealthtrackRx: Advisor/Consultant|UpToDate, Inc.: Author Royalties Melissa D. Johnson, PharmD MHS AAHIVP, Biomeme: Licensed technology, method to detect fungal infection|Biomeme: Licensed technology, method to detect fungal infection|Scynexis: Grant/Research Support|Scynexis: Grant/Research Support|UpToDate: Author Royalties|UpToDate: Author Royalties Rebekah W. Moehring, MD, MPH, FIDSA, FSHEA, UpToDate, Inc.: Author Royalties

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.1100
Primary Topic
Antibiotic Use and Resistance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-892. Reality of Resistance Data: Practical Applications of Risk Adjusted Antimicrobial Resistance Data Using The National Healthcare Safety Network Antimicrobial Use and Resistance Module

Anderson Dm, Angelina Davis, April Dyer, Jeannette Bouchard et al.
Open Forum Infectious Diseases
Antibiotic Use and Resistance
article

P-892. Reality of Resistance Data: Practical Applications of Risk Adjusted Antimicrobial Resistance Data Using The National Healthcare Safety Network Antimicrobial Use and Resistance Module

Anderson Dm, Angelina Davis, April Dyer, Jeannette Bouchard, Melissa D Johnson, Rebekah W Moehring
article en

Abstract

Abstract Background Beginning in 2024, US hospitals were required to participate in the CDC National Healthcare Safety Network (NHSN) antimicrobial use and resistance (AUR) module, which captures data on antimicrobial use (AU) and targeted antimicrobial resistance (AR) results. The AUR module outputs provide facility-level risk adjustment that enables inter-hospital benchmarking. While many stewards have experience using AU, end users are less familiar with AR module outputs. Also, national aggregate data reports of AR are not yet available. We describe an initial year of risk-adjusted output from the NHSN AR option for our network of 46 hospitals included in the Duke Antimicrobial Stewardship Outreach Network (DASON) NHSN Group. Methods AR data for each facility were reported in monthly increments following NHSN protocol specifications. A dataset was generated and reports for two risk-adjusted AR metrics were extracted: standardized resistant infection ratio (SRIR) and pathogen-specific standardized infection ratio (pSIR) for 2024. These observed to expected (O:E) ratios are calculated for hospital onset (collected after day 3 of admission) isolates. Data were summarized using descriptive measures. Results SRIRs were available for seven drug-resistant pathogen groups and three of the four anatomic sites captured in NHSN (blood, urine and lower respiratory tract). pSIRs were calculated for the same three sites for four pathogen groups. No risk adjusted metrics were available for cerebrospinal fluid specimens. Distributions for each of the 21 SRIR and 12 pSIR categories across 46 DASON hospitals (Tables 1 & 2) demonstrate great variability among hospitals. Specifically, effects of small populations on predicted isolate numbers were common in our community hospital network. Of 966 predicted isolate calculations (SRIR denominators) for 2024, (531) 55% were predicted to be less than one. Similarly, for the 552 predicted hospital onset pathogens, 132 (24%) were predicted to be less than one. Conclusion Early experience with AR data suggests that low predicted numbers of isolates may result in initially high observed to expected ratios. More experience on how to use and interpret hospitals’ AR risk-adjusted metrics in routine stewardship and prevention work is needed. Disclosures Elizabeth Dodds Ashley, PharmD, MHS, HealthtrackRx: Advisor/Consultant|UpToDate, Inc.: Author Royalties Melissa D. Johnson, PharmD MHS AAHIVP, Biomeme: Licensed technology, method to detect fungal infection|Biomeme: Licensed technology, method to detect fungal infection|Scynexis: Grant/Research Support|Scynexis: Grant/Research Support|UpToDate: Author Royalties|UpToDate: Author Royalties Rebekah W. Moehring, MD, MPH, FIDSA, FSHEA, UpToDate, Inc.: Author Royalties

Open Forum Infectious DiseasesVol. 13(Supplement_1)
Duke University (US)
Good health and well-being
Openalex Percentile: Top 91%
Antibiotic Use and Resistance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.